Revenue: As of FY2026 Q1, the actual value is USD 20.88 M, beating the estimate of USD 19.79 M.EPS: As of FY2026 Q1, the actual value is USD -0.02.EBIT: As of FY2026 Q1, the actual value is USD -2.543 M.<h4>Financial Highlights</h4>Total RevenueXtant Medical Holdings, Inc. generated total revenue of $20.9 million for the first quarter of 2026, a decrease from $32.9 million for the first quarter of 2025. This decline is primarily attributed to the sale of assets and businesses to Companion Spine in December 2025, as well as non-recurring license revenue from 2025. Product revenue was $20,884 thousand for Q1 2026, down from $29,284 thousand for Q1 2025. License revenue was $0 for Q1 2026, compared to $3,620 thousand for Q1 2025.Gross MarginGross margin for the first quarter of 2026 was 57.3%, down from 61.5% for the same period in 2025.Operating ExpensesTotal operating expenses for the first quarter of 2026 were $14.9 million, a reduction from $19.2 million for the first quarter of 2025.Net Income/LossThe company reported a net loss of - $3.1 million for the first quarter of 2026, compared to a net income of $58,000 for the first quarter of 2025.Non-GAAP Adjusted EBITDANon-GAAP adjusted EBITDA loss for the first quarter of 2026 totaled - $1.6 million, a decrease from a positive adjusted EBITDA of $3.0 million for the same period in 2025.<h4>Balance Sheet &amp; Indebtedness</h4>Total IndebtednessXtant Medical Holdings, Inc. reduced its total indebtedness by $13.3 million in the first quarter of 2026. Total indebtedness was $12.2 million as of March 31, 2026, down from $25.4 million as of December 31, 2025.Cash and Cash EquivalentsAs of March 31, 2026, the company had $12.2 million in cash and cash equivalents, compared to $17.3 million as of December 31, 2025.Revolving Credit FacilityAvailability under its revolving credit facility increased to $11.8 million as of March 31, 2026, from $3.8 million as of December 31, 2025.<h4>Cash Flow from Operating Activities</h4>Net Cash Used in Operating ActivitiesNet cash used in operating activities for the three months ended March 31, 2026, was - $2,114 thousand, compared to net cash provided by operating activities of $1,278 thousand for the same period in 2025.<h4>Operational Highlights</h4>Xtant Medical Holdings, Inc. announced an exclusive U.S. distribution agreement with Dilon Technologies for its HEMOBLAST® Bellows product, and hired Dilon’s approximately 20-person U.S. sales team. The company launched Trivium™ Shaped, an extension of its demineralized bone matrix allograft product line. Xtant Medical Holdings, Inc. received the final $10.7 million due from Companion Spine in March, completing the previously announced sale of its Coflex®/CoFix assets and international hardware business for a total cash purchase price of $21.4 million.<h4>Outlook / Guidance</h4>Xtant Medical Holdings, Inc. increased its full-year 2026 revenue guidance to a range of $101 million to $105 million, up from the previous range of $95 million to $99 million. This revised guidance reflects the anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows product following the exclusive license agreement. The company expects to drive topline growth and margin expansion through the integration of Dilon’s sales force and recent product launches.

Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M